Rhelion subsidiary Filament Health signs CHDR PEX010 supply deal
Filament Health signed a supply and licensing agreement with CHDR to provide PEX010 (1 mg and 5 mg) and placebos for a psilocybin study, with regulatory support; the study requires regulatory and ethics approval.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.